1. Indications:

Caboxib (Cabozantinib) 20 mg is indicated for the treatment of:

• Metastatic renal cell carcinoma (RCC)
• Hepatocellular carcinoma (HCC)
• Medullary thyroid cancer (MTC)

2. Pharmacology:

Caboxib (Cabozantinib) 20 mg exerts its pharmacological effects by inhibiting the activity of multiple receptor tyrosine kinases (RTKs), including MET, VEGFRs, and RET. By targeting these pathways, Caboxib inhibits tumor angiogenesis, cell proliferation, and metastasis, thereby suppressing tumor growth and improving patient outcomes.

3. Dosage and Administration:

The recommended dosage of Caboxib (Cabozantinib) 20 mg may vary depending on the type of cancer being treated and individual patient characteristics. Typically, the prescribed dose is 20 mg taken orally once daily, with or without food. Patients should adhere to the dosing schedule provided by their healthcare provider and continue treatment as long as clinically beneficial.

4. Interaction:

Caboxib (Cabozantinib) 20 mg may interact with other medications, including:

• Strong CYP3A4 inhibitors or inducers: Co-administration with drugs that affect CYP3A4 metabolism may alter the plasma concentration of Caboxib.
• Anticoagulants: Concurrent use may increase the risk of bleeding complications.

Patients should inform their healthcare provider about all medications they are taking, including prescription, over-the-counter, and herbal products, to minimize the risk of potential interactions.

5. Side Effects:

Common side effects associated with Caboxib (Cabozantinib) 20 mg may include:

• Fatigue
• Diarrhea
• Hypertension
• Nausea
• Decreased appetite
• Hand-foot syndrome (palmar-plantar erythrodysesthesia)

Patients should report any persistent or severe side effects to their healthcare provider for further evaluation and management.

6. Precautions and Warnings:

Before using Caboxib (Cabozantinib) 20 mg, patients should be aware of the following precautions:

• Caboxib may cause hypertension, so blood pressure should be monitored regularly during treatment.
• Patients with a history of thrombotic events or bleeding disorders may be at increased risk of complications with Caboxib therapy.
• Caboxib may cause reversible posterior leukoencephalopathy syndrome (RPLS), a rare neurological disorder characterized by headache, seizures, and visual disturbances.

7. Overdose Effects:

In case of overdose with Caboxib (Cabozantinib) 20 mg, supportive care should be initiated, and symptomatic treatment may be administered as necessary. There is no specific antidote for Caboxib overdose, and patients should seek immediate medical attention if overdose is suspected.